Mandate

Vinge has advised Ambea AB (publ) in connection with its refinancing

Vinge advised Ambea AB (publ), the leading care provider in Scandinavia, in connection with a refinancing in an aggregate amount of SEK 5,000,000,000.

On 31 October 2022 Ambea AB (publ) entered into an unsecured facility agreement with a bank syndicate comprised of three Nordic banks. The new facility agreement has an initial term of three years with a one year extension option and consist of a SEK 4,000,000,000 committed facility and an uncommitted accordion option of SEK 1,000,000,000.

The purpose of the facility agreement is to refinance certain outstanding loans under the previous SEK 4,500,000,000 facility agreement and to increase the Ambea group’s overall financial flexibility.

Vinges team consisted of partner Albert Wållgren together with Josefine Lanker and Sofia Haggren.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025